Follicular lymphoma

Diagnosis needs tissue architecture and immune markers, usually including a germinal-center B-cell pattern. BCL2 rearrangement is common but is not an isolated yes/no test for every case. Unusual sites or morphology may require expert review.

Grades 1–2 and many grade 3A cases generally follow an indolent pathway. Grade 3B, called follicular large B-cell lymphoma in WHO fifth-edition terminology, is managed differently, usually along an aggressive B-cell pathway. Pediatric-type and duodenal-type disease are also distinct; they should not simply inherit an adult nodal treatment plan.

PET/CT and selected marrow assessment establish distribution and can identify a site needing biopsy. FLIPI is a prognostic score; it is not by itself a command to start treatment. Stage IV often reflects marrow or widespread involvement and does not mean the same prognosis as metastatic solid cancer.

Tumor burden, symptoms and threatened organs drive treatment timing. A large or compressive mass, lymphoma-related cytopenias, symptomatic spleen enlargement, effusions or significant systemic symptoms can make treatment necessary even when the lymphoma is biologically slow-growing.

For asymptomatic low-burden advanced disease, observation is a structured option with planned reviews and instructions for new symptoms. It avoids treatment adverse effects until there is a clinical reason to intervene. Follow-up should be understandable and accessible, not just “come back if worse.”

Long-term randomized evidence shows that early rituximab can delay the need for subsequent treatment compared with watchful waiting. That endpoint is not proof of an overall-survival advantage. Preference, anxiety, infection risk, treatment burden and access can influence the choice.

Truly localized disease can sometimes be treated with involved-site radiation with a durable-control or potentially curative aim. Accurate staging is important before committing to a local strategy. Observation or systemic approaches may be appropriate in selected circumstances.

Very-low-dose radiation is useful for selected symptom-control or response-adapted strategies, but it is not equivalent to a standard definitive dose. In FoRT, 4 Gy gave less durable local control than 24 Gy. The intended goal and nearby organ risks should guide planning.

Common approaches pair an anti-CD20 antibody such as rituximab or obinutuzumab with an appropriate systemic backbone. Chemotherapy choices differ in infection, marrow, cardiac and neuropathy risks. Lenalidomide-based approaches can avoid conventional chemotherapy in selected settings, but still have substantial monitoring and reproductive-safety requirements.

Maintenance antibody treatment can prolong disease control in some settings, with a trade-off in infections and treatment burden. Ask what outcome it improves for your regimen, how long treatment continues and how immune recovery will be followed.

POD24 describes early progression within a defined 24-month period after initial treatment in commonly used studies; the exact starting point should be checked. It identifies a group needing careful reassessment, not a fixed individual life expectancy. It does not by itself prove transformation.

Rapid growth at one site, new marked B symptoms or rising LDH may prompt PET-directed biopsy. Transformation to DLBCL changes the treatment pathway. If the disease remains indolent, the next choice depends on symptoms, previous response duration, prior toxicity and available treatment classes.

The US now authorizes tafasitamab with lenalidomide and rituximab, and epcoritamab with lenalidomide and rituximab, for relapsed/refractory FL. These are distinct combinations; adding an antibody is not a guarantee of better tolerability. Prior therapy, cytopenias, infection risk and practical burden remain important.

Later-line options include eligible CD20×CD3 bispecific monotherapy, zanubrutinib with obinutuzumab, and CD19 CAR-T. Product labels specify previous lines and disease; a therapy approved after at least two lines should not automatically be moved to first relapse. Mosunetuzumab has intravenous and subcutaneous formulations with different administration schedules.

CAR-T is a finite cell-treatment procedure with preparation and prolonged follow-up; bispecific treatment has its own schedule and monitoring. Both can cause serious immune toxicity, infections and low blood counts. Cross-trial response rates cannot decide which is best for an individual.

Tazemetostat (Tazverik), once an option for selected FL, is an important example. Following an increased risk of new blood cancers in the confirmatory program, its US approval was withdrawn, effective in June 2026. It should not remain on a page as an ordinary currently approved US option.

An EZH2 result therefore does not, by itself, establish access to this medicine. If an older report recommends it, ask the treating team to recheck the regulatory status and alternatives. People already receiving treatment should arrange a clinical transition plan rather than change therapy independently.

Repeated treatment can affect immune recovery. Hepatitis B prevention, infection history, immunoglobulins when relevant, vaccination timing and blood-count recovery deserve attention. Fever during immunosuppressive treatment needs prompt contact with the care team.

Bring the original grade and pathology, any repeat biopsy, PET/CT images, dates and duration of each remission, maintenance exposure and infection/toxicity history. Ask whether treatment is needed now, whether transformation has been excluded, and how the proposed choice preserves later options.